Ozempic (semaglutide) is a GLP-1 receptor agonist originally for type 2 diabetes that suppresses appetite and slows digestion, leading to gradual weight loss (10–15% in a year). Common side effects in ...
Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...
The US Food and Drug Administration intends to put a “black box” warning on Covid-19 vaccines, according to two people ...
FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from ...
Leaders at the U.S. Food and Drug Administration have pressed internally for reviewers to speed up their evaluation of Eli ...
An anti-vaccine organization founded by HHS Secretary Robert F. Kennedy Jr. is urging the FDA he now oversees to pull the ...
"Considering the urgent global need for new gonorrhea treatments, the finding that a single-dose of oral zoliflodacin was efficacious at curing urogenital and rectal and pharyngeal gonorrhoea is ...
In a closely watched case, the U.S. solicitor general urged the Supreme Court to review a controversy over so-called skinny ...
Tarlatamab-dlle received FDA approval for ES-SCLC after showing a 40% reduction in death risk compared with chemotherapy in the DeLLphi-304 trial. The trial demonstrated improved overall survival ...
The FDA has converted its accelerated approval to a standard one for tarlatamab in extensive-stage small cell lung cancer. The FDA has converted its 2024 accelerated approval of tarlatamab-dlle ...
WASHINGTON (AP) — Hormone-based drugs used to treat hot flashes and other menopause symptoms will no longer carry a bold warning label about stroke, heart attack, dementia and other serious risks, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback